BPH Treatment Device Market Size, Share & Trend Analysis - Global - 2025-2031 - Includes: TURP Market, Laser BPH Fibre Treatment Market, and 2 more
Description
Global BPH Treatment Device Market Report, 2025 Edition
Executive Summary
The global benign prostatic hyperplasia (BPH) treatment device market was valued at over $1.0 billion in 2024. The market is expected to grow at a 5.1 percent CAGR to exceed $1.4 billion by 2032. Growth is driven by demographic aging, expanding access to minimally invasive treatments, and the ongoing shift away from traditional surgery toward office based and day surgery procedures.
This report covers the full spectrum of BPH treatment technologies, including transurethral resection of the prostate (TURP), laser BPH systems, UroLift®, and Rezūm®. Within TURP, the market is segmented into monopolar and bipolar electrodes. The laser BPH segment includes high power holmium equipment and dedicated fibers, as well as thulium equipment and fibers. The UroLift and Rezūm markets are defined by their procedure specific consumables.
The analysis quantifies units sold, average selling prices, market values, growth rates, and company shares. It also evaluates procedure volumes, market drivers and limiters, reimbursement dynamics, and emerging technologies. Historical data to 2022 and forecasts through 2032 are included.
Both Rezūm and UroLift are relatively new treatment options that offer non invasive or minimally invasive alternatives for BPH patients who wish to avoid traditional surgery or preserve sexual function. These technologies are currently adopted primarily in the United States and Western Europe. As reimbursement expands to additional countries and payers, their global uptake is expected to increase significantly.
The global BPH treatment device market sits at the intersection of urology, aging demographics, chronic symptom management, and health policy. This report provides an integrated view of how these forces shape long term demand for capital equipment and procedure driven consumables.
Market Overview
Benign prostatic hyperplasia is a common condition that affects men as they age, often beginning after age 50. Enlargement of the prostate can compress the urethra and cause lower urinary tract symptoms, including weak stream, increased frequency, nocturia, and incomplete emptying. While drug therapy remains the first line of treatment for most patients, interventional procedures are required when medications fail to provide sufficient relief or when complications develop.
The BPH treatment device market includes four main categories:
TURP
The longstanding surgical standard, performed with monopolar or bipolar electrodes. TURP removes prostate tissue to relieve obstruction and is typically carried out in a hospital setting under anesthesia.
Laser BPH
Laser based procedures that vaporize or enucleate excess tissue. This category includes high power holmium systems and fibers, as well as thulium equipment and fibers. Laser procedures offer better hemostasis and can shorten hospital stays compared with traditional TURP.
UroLift
A minimally invasive procedure that uses implants to retract prostate tissue away from the urethra without cutting or removing tissue. UroLift is usually performed in an outpatient or office setting.
Rezūm
A minimally invasive therapy that uses water vapor thermal energy to ablate prostate tissue. Rezūm is also typically performed in an office or day surgery environment.
Both UroLift and Rezūm are designed to bridge the treatment gap between long term drug therapy and invasive surgery. They appeal to patients who are reluctant to undergo TURP or laser surgery and who prefer procedures that can often be done under local anesthesia with shorter recovery times.
The current global market is highly influenced by regional reimbursement and clinical practice patterns. In many countries, TURP and laser procedures are well established, while UroLift and Rezūm are still in early stages of adoption. As health systems assess cost effectiveness, patient satisfaction, and long term outcomes, the relative share of each modality will continue to evolve.
Market Drivers
Demographic Factors
BPH is strongly associated with age. As the global population of men over 50 continues to grow, particularly in developed regions, the number of BPH diagnoses and symptomatic patients increases. The aging baby boomer population in North America and Europe is a major contributor to procedure volumes.
An older male population means more patients moving through the treatment pathway, starting with watchful waiting, progressing to medications, and eventually requiring interventional treatment when symptoms worsen or complications arise. This demographic backdrop supports stable long term demand for all categories of BPH treatment devices.
Healthcare Reform and Care Setting Shifts
Changes in healthcare organization, especially in the United States, are shifting the way BPH care is delivered. Many private practice urologists have moved into hospital or large group practice employment models. While private physicians can choose whether to accept certain payers, hospitals and integrated delivery networks generally care for Medicare and Affordable Care Act insured patients as part of their mandate.
As patient volumes for older men increase, hospitals seek efficient ways to manage BPH within existing resources. Minimally invasive technologies that reduce hospital stays, allow procedures in ambulatory or office settings, and lower complication rates fit well with these goals. This trend supports the expansion of laser BPH, UroLift, and Rezūm in health systems focused on throughput and cost effectiveness.
Technological Development and New Treatment Options
Rezūm and UroLift represent clinically meaningful innovations in the BPH treatment pathway. Both therapies are relatively new and primarily adopted in developed markets such as the United States and Western Europe. They provide non invasive or minimally invasive options that can preserve sexual function and shorten recovery times.
Many patients remain on medications for years because they wish to avoid surgery. As awareness of UroLift and Rezūm grows among urologists, primary care physicians, and patients, more men may choose earlier interventional treatment instead of prolonged drug therapy alone. This can increase the number of procedures and overall device usage.
These markets are still young, and many countries have not yet adopted or reimbursed these treatments. As payers in additional regions begin reimbursing for UroLift and Rezūm, device utilization and market value are expected to grow significantly.
Market Limiters
Reimbursement Constraints
Reimbursement is a critical factor for newer technologies. For Rezūm and UroLift, reimbursement is relatively well established in the United States but more limited in other regions. In markets where reimbursement is absent or unclear, hospitals and physicians are less likely to adopt these procedures routinely.
Providers often favor procedures with clearly defined payment codes and predictable coverage, particularly in cost constrained environments. Delays in obtaining reimbursement for new technologies limit their global rollout and slow procedure growth outside early adopter markets.
Dominance of Drug Therapy
The strongest limiter of the BPH treatment device market is the extensive use of pharmaceutical therapy. In 2024, more than 90 percent of BPH patients were treated with medications rather than interventional procedures. Drug therapy is often tried for at least six months before patients and physicians consider surgical options.
Even after interventional procedures, many patients are advised to continue medications to reduce symptom recurrence. As new drugs and combination regimens enter the market, they may further postpone or reduce the need for device based treatments.
While medications do not remove excess prostate tissue, they can manage symptoms well enough for many patients to avoid or delay surgery. This dynamic caps the share of BPH patients who reach the procedural stage in any given year.
Risk of Complications
Interventional BPH treatments always carry more risk than watchful waiting or drug therapy. Traditional TURP in particular is associated with potential complications, such as bleeding, electrolyte disturbances, and sexual dysfunction including impotence and retrograde ejaculation. TURP also requires anesthesia and postoperative hospitalization.
As a result, some urologists are increasingly cautious about recommending TURP, especially for patients with comorbidities or those concerned about sexual side effects. Patients may also be reluctant to undergo invasive surgery and instead opt to remain on medications, even if symptoms are only partially controlled.
While laser BPH, UroLift, and Rezūm often improve the safety profile compared with TURP, perceptions about risk still influence patient and physician decisions and may limit procedure volumes.
Market Coverage and Data Scope
Quantitative Coverage
Market size
Market shares
Unit sales
Average selling prices
Market forecasts to 2032
Market growth rates
Qualitative Coverage
Market growth trends
Market limiters
Competitive analysis and SWOT for top competitors
Company profiles and product portfolios
Mergers and acquisitions
Regulatory and reimbursement landscape
Disease and treatment pathway overviews
Data Sources
Primary interviews with industry leaders and urology specialists
Government physician and procedure data
Regulatory data
Hospital procurement and utilization data
Import and export records
iData Research internal database and forecasting models
Markets Covered and Segmentation
Global BPH Treatment Device Market Segmentation Summary
TURP Market
Monopolar electrodes
Bipolar electrodes
Laser BPH Market
Equipment
Holmium laser systems
Thulium laser systems
Fiber
Holmium laser fibers
Thulium laser fibers
UroLift
Procedure specific consumables and implants
Rezūm
Procedure specific consumables and delivery systems
For each segment, the report provides unit, ASP, and revenue data by region and country, along with historical trends and forecasts through 2032.
Competitive Analysis
Teleflex
Teleflex was the leading competitor in the global BPH treatment device market in 2024. This leadership is entirely due to its position in the UroLift segment, where Teleflex is the sole player. UroLift has gained strong traction among urologists who wish to offer a minimally invasive, implant based therapy that can be performed in an office or ambulatory setting with a favorable sexual side effect profile.
As Teleflex expands training programs, clinical evidence, and geographic reach, UroLift procedure volumes are expected to continue growing in markets where reimbursement is favorable.
Boston Scientific
Boston Scientific was the second leading competitor in 2024. The company holds a dominant share in the laser BPH market and a monopolistic position in the Rezūm segment. In laser BPH, Boston Scientific competes with VersaPulse PowerSuite holmium laser systems and the high power Lumenis Pulse series of holmium lasers.
The acquisition of the global surgical business of Lumenis in 2021 strengthened Boston Scientific’s laser portfolio and expanded its installed base across hospitals and surgical centers. The company’s leadership in Rezūm further reinforces its presence in minimally invasive BPH therapies.
Olympus
Olympus ranked as the third leading competitor in the BPH treatment device market. Its position stems from strong participation in both the TURP and laser BPH segments. Olympus offers PlasmaButton and related vaporization electrodes, which allow simultaneous tissue vaporization and coagulation during TURP procedures.
In addition, Olympus invested in Medi Tates in 2018, gaining exclusive rights to market the iTind (Temporarily Implanted Nitinol Device) in selected regions. This investment reflects Olympus’ strategy to expand into newer minimally invasive BPH solutions alongside its traditional TURP and laser offerings.
Technology and Practice Trends
Gradual shift from monopolar to bipolar TURP due to better safety profiles
Expansion of laser BPH procedures using holmium and thulium systems
Increased adoption of office based treatments like UroLift and Rezūm for selected patients
Integration of minimally invasive therapies into earlier stages of the treatment pathway
Stronger emphasis on patient reported outcomes, including preservation of sexual function
Growing use of day surgery and ambulatory settings for BPH procedures
Continued focus on shortening length of stay and reducing complications under value based care models
These trends support continued diversification of BPH treatment options and will likely redistribute procedure volumes across TURP, laser BPH, UroLift, and Rezūm segments over time.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
This report helps you answer key strategic questions, including:
Where are the largest and fastest growing opportunities across TURP, laser BPH, UroLift, and Rezūm
How demographic aging and obesity trends will drive procedure volumes for BPH treatment
How new minimally invasive therapies will reshape the balance between drug therapy and surgery
How reimbursement constraints and drug competition will affect market growth by region
Which competitors are best positioned to capture share in laser BPH and minimally invasive segments
How unit and pricing trends vary between capital equipment and procedure driven consumables
How health policy, care settings, and value based purchasing influence technology selection
The Global BPH Treatment Device Market Report from iData Research provides the data and insight necessary to quantify demand, evaluate competition, and plan product, pricing, and market entry strategies.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Executive Summary
The global benign prostatic hyperplasia (BPH) treatment device market was valued at over $1.0 billion in 2024. The market is expected to grow at a 5.1 percent CAGR to exceed $1.4 billion by 2032. Growth is driven by demographic aging, expanding access to minimally invasive treatments, and the ongoing shift away from traditional surgery toward office based and day surgery procedures.
This report covers the full spectrum of BPH treatment technologies, including transurethral resection of the prostate (TURP), laser BPH systems, UroLift®, and Rezūm®. Within TURP, the market is segmented into monopolar and bipolar electrodes. The laser BPH segment includes high power holmium equipment and dedicated fibers, as well as thulium equipment and fibers. The UroLift and Rezūm markets are defined by their procedure specific consumables.
The analysis quantifies units sold, average selling prices, market values, growth rates, and company shares. It also evaluates procedure volumes, market drivers and limiters, reimbursement dynamics, and emerging technologies. Historical data to 2022 and forecasts through 2032 are included.
Both Rezūm and UroLift are relatively new treatment options that offer non invasive or minimally invasive alternatives for BPH patients who wish to avoid traditional surgery or preserve sexual function. These technologies are currently adopted primarily in the United States and Western Europe. As reimbursement expands to additional countries and payers, their global uptake is expected to increase significantly.
The global BPH treatment device market sits at the intersection of urology, aging demographics, chronic symptom management, and health policy. This report provides an integrated view of how these forces shape long term demand for capital equipment and procedure driven consumables.
Market Overview
Benign prostatic hyperplasia is a common condition that affects men as they age, often beginning after age 50. Enlargement of the prostate can compress the urethra and cause lower urinary tract symptoms, including weak stream, increased frequency, nocturia, and incomplete emptying. While drug therapy remains the first line of treatment for most patients, interventional procedures are required when medications fail to provide sufficient relief or when complications develop.
The BPH treatment device market includes four main categories:
TURP
The longstanding surgical standard, performed with monopolar or bipolar electrodes. TURP removes prostate tissue to relieve obstruction and is typically carried out in a hospital setting under anesthesia.
Laser BPH
Laser based procedures that vaporize or enucleate excess tissue. This category includes high power holmium systems and fibers, as well as thulium equipment and fibers. Laser procedures offer better hemostasis and can shorten hospital stays compared with traditional TURP.
UroLift
A minimally invasive procedure that uses implants to retract prostate tissue away from the urethra without cutting or removing tissue. UroLift is usually performed in an outpatient or office setting.
Rezūm
A minimally invasive therapy that uses water vapor thermal energy to ablate prostate tissue. Rezūm is also typically performed in an office or day surgery environment.
Both UroLift and Rezūm are designed to bridge the treatment gap between long term drug therapy and invasive surgery. They appeal to patients who are reluctant to undergo TURP or laser surgery and who prefer procedures that can often be done under local anesthesia with shorter recovery times.
The current global market is highly influenced by regional reimbursement and clinical practice patterns. In many countries, TURP and laser procedures are well established, while UroLift and Rezūm are still in early stages of adoption. As health systems assess cost effectiveness, patient satisfaction, and long term outcomes, the relative share of each modality will continue to evolve.
Market Drivers
Demographic Factors
BPH is strongly associated with age. As the global population of men over 50 continues to grow, particularly in developed regions, the number of BPH diagnoses and symptomatic patients increases. The aging baby boomer population in North America and Europe is a major contributor to procedure volumes.
An older male population means more patients moving through the treatment pathway, starting with watchful waiting, progressing to medications, and eventually requiring interventional treatment when symptoms worsen or complications arise. This demographic backdrop supports stable long term demand for all categories of BPH treatment devices.
Healthcare Reform and Care Setting Shifts
Changes in healthcare organization, especially in the United States, are shifting the way BPH care is delivered. Many private practice urologists have moved into hospital or large group practice employment models. While private physicians can choose whether to accept certain payers, hospitals and integrated delivery networks generally care for Medicare and Affordable Care Act insured patients as part of their mandate.
As patient volumes for older men increase, hospitals seek efficient ways to manage BPH within existing resources. Minimally invasive technologies that reduce hospital stays, allow procedures in ambulatory or office settings, and lower complication rates fit well with these goals. This trend supports the expansion of laser BPH, UroLift, and Rezūm in health systems focused on throughput and cost effectiveness.
Technological Development and New Treatment Options
Rezūm and UroLift represent clinically meaningful innovations in the BPH treatment pathway. Both therapies are relatively new and primarily adopted in developed markets such as the United States and Western Europe. They provide non invasive or minimally invasive options that can preserve sexual function and shorten recovery times.
Many patients remain on medications for years because they wish to avoid surgery. As awareness of UroLift and Rezūm grows among urologists, primary care physicians, and patients, more men may choose earlier interventional treatment instead of prolonged drug therapy alone. This can increase the number of procedures and overall device usage.
These markets are still young, and many countries have not yet adopted or reimbursed these treatments. As payers in additional regions begin reimbursing for UroLift and Rezūm, device utilization and market value are expected to grow significantly.
Market Limiters
Reimbursement Constraints
Reimbursement is a critical factor for newer technologies. For Rezūm and UroLift, reimbursement is relatively well established in the United States but more limited in other regions. In markets where reimbursement is absent or unclear, hospitals and physicians are less likely to adopt these procedures routinely.
Providers often favor procedures with clearly defined payment codes and predictable coverage, particularly in cost constrained environments. Delays in obtaining reimbursement for new technologies limit their global rollout and slow procedure growth outside early adopter markets.
Dominance of Drug Therapy
The strongest limiter of the BPH treatment device market is the extensive use of pharmaceutical therapy. In 2024, more than 90 percent of BPH patients were treated with medications rather than interventional procedures. Drug therapy is often tried for at least six months before patients and physicians consider surgical options.
Even after interventional procedures, many patients are advised to continue medications to reduce symptom recurrence. As new drugs and combination regimens enter the market, they may further postpone or reduce the need for device based treatments.
While medications do not remove excess prostate tissue, they can manage symptoms well enough for many patients to avoid or delay surgery. This dynamic caps the share of BPH patients who reach the procedural stage in any given year.
Risk of Complications
Interventional BPH treatments always carry more risk than watchful waiting or drug therapy. Traditional TURP in particular is associated with potential complications, such as bleeding, electrolyte disturbances, and sexual dysfunction including impotence and retrograde ejaculation. TURP also requires anesthesia and postoperative hospitalization.
As a result, some urologists are increasingly cautious about recommending TURP, especially for patients with comorbidities or those concerned about sexual side effects. Patients may also be reluctant to undergo invasive surgery and instead opt to remain on medications, even if symptoms are only partially controlled.
While laser BPH, UroLift, and Rezūm often improve the safety profile compared with TURP, perceptions about risk still influence patient and physician decisions and may limit procedure volumes.
Market Coverage and Data Scope
Quantitative Coverage
Market size
Market shares
Unit sales
Average selling prices
Market forecasts to 2032
Market growth rates
Qualitative Coverage
Market growth trends
Market limiters
Competitive analysis and SWOT for top competitors
Company profiles and product portfolios
Mergers and acquisitions
Regulatory and reimbursement landscape
Disease and treatment pathway overviews
Data Sources
Primary interviews with industry leaders and urology specialists
Government physician and procedure data
Regulatory data
Hospital procurement and utilization data
Import and export records
iData Research internal database and forecasting models
Markets Covered and Segmentation
Global BPH Treatment Device Market Segmentation Summary
TURP Market
Monopolar electrodes
Bipolar electrodes
Laser BPH Market
Equipment
Holmium laser systems
Thulium laser systems
Fiber
Holmium laser fibers
Thulium laser fibers
UroLift
Procedure specific consumables and implants
Rezūm
Procedure specific consumables and delivery systems
For each segment, the report provides unit, ASP, and revenue data by region and country, along with historical trends and forecasts through 2032.
Competitive Analysis
Teleflex
Teleflex was the leading competitor in the global BPH treatment device market in 2024. This leadership is entirely due to its position in the UroLift segment, where Teleflex is the sole player. UroLift has gained strong traction among urologists who wish to offer a minimally invasive, implant based therapy that can be performed in an office or ambulatory setting with a favorable sexual side effect profile.
As Teleflex expands training programs, clinical evidence, and geographic reach, UroLift procedure volumes are expected to continue growing in markets where reimbursement is favorable.
Boston Scientific
Boston Scientific was the second leading competitor in 2024. The company holds a dominant share in the laser BPH market and a monopolistic position in the Rezūm segment. In laser BPH, Boston Scientific competes with VersaPulse PowerSuite holmium laser systems and the high power Lumenis Pulse series of holmium lasers.
The acquisition of the global surgical business of Lumenis in 2021 strengthened Boston Scientific’s laser portfolio and expanded its installed base across hospitals and surgical centers. The company’s leadership in Rezūm further reinforces its presence in minimally invasive BPH therapies.
Olympus
Olympus ranked as the third leading competitor in the BPH treatment device market. Its position stems from strong participation in both the TURP and laser BPH segments. Olympus offers PlasmaButton and related vaporization electrodes, which allow simultaneous tissue vaporization and coagulation during TURP procedures.
In addition, Olympus invested in Medi Tates in 2018, gaining exclusive rights to market the iTind (Temporarily Implanted Nitinol Device) in selected regions. This investment reflects Olympus’ strategy to expand into newer minimally invasive BPH solutions alongside its traditional TURP and laser offerings.
Technology and Practice Trends
Gradual shift from monopolar to bipolar TURP due to better safety profiles
Expansion of laser BPH procedures using holmium and thulium systems
Increased adoption of office based treatments like UroLift and Rezūm for selected patients
Integration of minimally invasive therapies into earlier stages of the treatment pathway
Stronger emphasis on patient reported outcomes, including preservation of sexual function
Growing use of day surgery and ambulatory settings for BPH procedures
Continued focus on shortening length of stay and reducing complications under value based care models
These trends support continued diversification of BPH treatment options and will likely redistribute procedure volumes across TURP, laser BPH, UroLift, and Rezūm segments over time.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
This report helps you answer key strategic questions, including:
Where are the largest and fastest growing opportunities across TURP, laser BPH, UroLift, and Rezūm
How demographic aging and obesity trends will drive procedure volumes for BPH treatment
How new minimally invasive therapies will reshape the balance between drug therapy and surgery
How reimbursement constraints and drug competition will affect market growth by region
Which competitors are best positioned to capture share in laser BPH and minimally invasive segments
How unit and pricing trends vary between capital equipment and procedure driven consumables
How health policy, care settings, and value based purchasing influence technology selection
The Global BPH Treatment Device Market Report from iData Research provides the data and insight necessary to quantify demand, evaluate competition, and plan product, pricing, and market entry strategies.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Table of Contents
163 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
